NCT04478279 - A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

125

Participants

Timeline

Start Date

July 1, 2020

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

GlioblastomaMelanoma Stage IVBreast CancerProstate CancerGlioblastoma MultiformeGBMBrain CancerMetastatic Breast CancerMetastatic MelanomaMetastatic Prostate CancerMelanoma RecurrentProstate Cancer MetastaticRecurrent GlioblastomaNewly Diagnosed Glioblastoma

Interventions

DRUG

ST101

ST101 will be administered intravenously (IV), initially once per week with a flat dose on the schedule described for each study arm

DRUG

Temozolomide

RADIATION

Radiation

Trial Locations (11)

10032

Columbia University, New York

27708

Duke University School of Medicine, Durham

37203

Sarah Cannon Research Institute, Nashville

49503

START Midwest, Grand Rapids

60555

Northwestern Medicine Cancer Centers, Warrenville

80218

Sarah Cannon Research Institute, Denver

94143

University of California, San Francisco, San Francisco

EH4 2SP

Edinburgh Cancer Centre, Edinburgh

G12 0YN

The Beaston West of Scotland Cancer Centre, Glasgow

LS9 7TF

University of Leeds, Leeds

W1G 6AD

Sarah Cannon Research Institute UK, London